VEGF-modulated genes and methods employing them

An isolated polynucleotide comprising a nucleotide sequence having at least 80% sequence identity to the sequence SEQ ID NO:2 or SEQ ID NO:21, or a complement of said polynucleotide.

A method of modulating angiogenesis comprising modulating the activity of at least one VEGF-modulated gene polypeptide.

A method of measuring a VEGF-modulated gene transcriptional up-regulation or down-regulation activity of a compound, comprising:

• contacting said compound with a composition comprising a RNA polymerase and said gene and measuring the amount of VEGF-modulated gene transcription.

A method of measuring VEGF-modulated gene translational up-regulation or down-regulation activity of a compound, comprising:

• contacting said compound with a composition comprising a ribosome and a polynucleotide corresponding to a mRNA of said gene and measuring the amount of VEGF-modulated gene translation.

A method of screening a tissue sample for tumorigenic potential, comprising:

• measuring expression of at least one VEGF-modulated gene in said tissue sample.

A transgenic non-human animal, having a disrupted ARP.

A transgenic non-human animal, comprising an exogenous polynucleotide having at least 80% sequence identity to the sequence SEQ ID NO:2 or SEQ ID NO:21, or a complement of said polynucleotide.

A method of screening a sample for an ARP mutation, comprising:

• comparing an ARP nucleotide sequence in the sample with SEQ ID NO:2 or SEQ ID NO:21.

A method of modulating cell survival by modulating the activity of at least one VEGF-modulated gene polypeptide selected from the group consisting of nexin, PP5, APLP2, APP, gravin, ARP, DSCR1, MTCO1, ND1, ND4, HB-EGF, MKP-1 like protein tyrosine phosphatase, osteonidogen and CTGF.

A method of determining the clinical stage of tumor comprising comparing expression of at least one VEGF-modulated gene in a sample with expression of said at least one gene in control samples.